Relapse of autoimmune diseases after liver transplantation
https://doi.org/10.23873/2074-0506-2022-14-4-421-431
Abstract
Background. The recurrence of autoimmune liver diseases can lead to reduced survival of recipients and grafts.
Aim. To study the incidence and impact of the recurrence of autoimmune liver diseases on graft survival; the effect of maintenance immunosuppression on the recurrence of autoimmune diseases in liver transplant recipients
Material and methods. Transplantation outcomes in 111 recipients (21 recipients operated on for autoimmune hepatitis, 50 recipients operated on for primary biliary cirrhosis, and 40 recipients operated on for primary sclerosing cholangitis) were analyzed retrospectively.
Results. The recurrence of autoimmune hepatitis is observed in 5%, the recurrence of primary biliary cirrhosis is in 10%, and the recurrence of primary sclerosing cholangitis is in 17% of cases. Among patients with recurrence of autoimmune diseases, men accounted for 54%, while for only 31% in the subgroup of patients without relapse (p=0.004). The followup for recipients with relapse (64.5 (42.8;82.0) months) was comparable to the follow-up for recipients without relapse (46.5 (17.9;103.5) months, p=0.54). A ten-year graft survival was significantly higher in the group of recipients with recurrent autoimmune diseases compared with recipients without autoimmune diseases recurrence (p<0.0001).
Conclusions. The recurrence of autoimmune diseases leads to a decrease in graft survival. The effect of immunosuppression components on the risk of recurrence of autoimmune diseases in the graft has not been established.
About the Authors
V. E. Syutkin
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Vladimir E. Syutkin, Dr. Sci. (Med.), Leading Research Associate, Department for Liver Transplantation
3 Bolshaya Sukharevskaya Sq., Moscow 129090
A. A. Salienko
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Anastasiya A. Salienko, Surgeon, Researcher of the Department for Liver Transplantation
3 Bolshaya Sukharevskaya Sq., Moscow 129090
O. D. Olisov
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Oleg D. Olisov, Cand. Sci. (Med.), Senior Researcher of the Department for Liver Transplantation
3 Bolshaya Sukharevskaya Sq., Moscow 129090
M. S. Novruzbekov
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Murad S. Novruzbekov, Dr. Sci. (Med.), Head of the Scientific Department for Liver Transplantation
3 Bolshaya Sukharevskaya Sq., Moscow 129090
References
1. Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther. 2017;45(4):485–500. PMID: 27957759 https://doi.org/0.1111/apt.13894
2. Visseren T, Darwish Murad S. Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and autoimmune hepatitis after liver transplantation. Best Pract Res Clin Gastroenterol. 2017;31(2):187–198. PMID: 28624107 https://doi.org/10.1016/j.bpg.2017.04.004
3. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl. 2003;9(6):539–546. PMID: 12783392 https://doi.org/10.1053/jlts.2003.50096
4. Hubscher SG, Elias E, Buckels JA, Mayer AD, McMaster P, Neuberger JM. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol. 1993;18(2):173–184. PMID: 8409333 https://doi.org/10.1016/s01688278(05)80244-2
5. Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci. 2012;57(9):2248–2266. PMID: 22562533 https://doi.org/10.1007/s10620-0122179-3
6. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29(4):1050–1056. PMID: 10094945 https://doi.org/10.1002/hep.510290427
7. Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(10):1254–1261. PMID: 19790153 https://doi.org/10.1002/lt.21796
8. Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. World J Gastroenterol. 2008;14(21):3388– 3395. PMID: 18528936 https://doi.org/10.3748/wjg.14.3388
9. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int. 2008;21(5):459–465. PMID: 18225996 https://doi.org/10.1111/j.14322277.2007.00628.x
10. Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis DN, et al. Immunosuppressive treatment regimens in autoimmune hepatitis: systematic reviews and meta-analyses supporting American Association for the Study of Liver Diseases Guidelines. Hepatology. 2020;72(2):753–769. PMID: 32500593 https://doi.org/10.1002/hep.31407
11. Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139– 1146. PMID: 26186988 https://doi.org/10.1016/j.jhep.2015.07.005
12. Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med. 1982;306(1):1–4. PMID: 7031471 https://doi.org/10.1056/NEJM198201073060101
13. Aguilar MT, Carey EJ. Current status of liver transplantation for primary biliary cholangitis. Clin Liver Dis. 2018;22(3):613–624. PMID: 30259857 https://doi.org/10.1016/j.cld.2018.03.011
14. Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G, et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2010;16(1):64–73. PMID: 19866449 https://doi.org/10.1002/lt.21960
15. Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology. 2019;156(1):96–107.e1. PMID: 30296431 https://doi.org/10.1053/j.gastro.2018.10.001
16. Montano-Loza AJ, Ebadi M, Mason AL. Reply to: "Recurrence of primary biliary cholangitis after liver transplantation: Is Tacrolimus really worse than other drugs?" and "Goodbye for good: stepping away from recurrence". Gastroenterology. 2019:S0016–5085(19)36732–0. PMID: 31039341 https://doi.org/10.1053/j.gastro.2019.04.039
17. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2004;10(4):488–491. PMID: 15048790 https://doi.org/10.1002/lt.20123
18. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12(12):1813– 1824. PMID: 17031826 https://doi.org/10.1002/lt.20910
19. Pedersen MR, Greenan G, Arora S, Murali AR, Mayo MJ. Ursodeoxycholic acid decreases incidence of primary biliary cholangitis and biliary complications after liver transplantation: a metaanalysis. Liver Transpl. 2021;27(6):866–875. PMID: 33185320 https://doi.org/10.1002/lt.25935
Review
For citations:
Syutkin V.E., Salienko A.A., Olisov O.D., Novruzbekov M.S. Relapse of autoimmune diseases after liver transplantation. Transplantologiya. The Russian Journal of Transplantation. 2022;14(4):421-431. https://doi.org/10.23873/2074-0506-2022-14-4-421-431
Views:
763
Email this article 